| 前收市價 | 1.6500 |
| 開市 | 1.6000 |
| 買盤 | 1.4000 |
| 賣出價 | 1.6000 |
| 拍板 | 82.50 |
| 到期日 | 2024-07-19 |
| 今日波幅 | 1.4600 - 1.7000 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 76 |
ZacksPfizer (PFE), BioNTech's Updated COVID-19 Jab Gets CHMP Nod
Pfizer (PFE) and BioNTech's Omicron JN.1-adapted COVID-19 vaccine gets the Committee for Medicinal Products for Human Use's positive opinion recommending marketing authorization.
BenzingaCovid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a treatment forpatients suffering from specific type of endometrial cancer. Its pharma peer, BioNTech SE (NASDAQ: BNTX) wasn’t as lucky as also on Monday, the FDA put its experimental cancer drug study on partial clinical hold. Combining Immunotherapy And Chemotherapy Is Emerging As A New Standard In Ca
BloombergBioNTech Cancer Drug Licensed From MediLink Faces FDA Delay
(Bloomberg) -- The Food and Drug Administration delayed a breast- and lung-cancer trial of an experimental treatment that BioNTech SE licensed from Chinese biotech MediLink Therapeutics Ltd., citing safety concerns.Most Read from BloombergFlesh-Eating Bacteria That Can Kill in Two Days Spreads in JapanS&P 500 Hits 30th Record of 2024 as Megacaps Rally: Markets WrapThese Are the World’s Most Expensive Cities for Expats in 2024Hedge Funds’ Secret Weapon to Fight the SEC Lives in TexasHow the US Mo
